mavrilimumab

Kiniksa inks licensing deal to take a Regeneron castoff into Asian markets
Endpoints
Wed, 02/23/22 - 10:31 am
Kiniksa Pharmaceuticals
Regeneron
Arcalyst
Huadong Medicine
Asia
mavrilimumab
AstraZeneca reports mavrilimumab, sifalimumab studies met primary endpoints
The Fly on the Wall
Mon, 05/12/14 - 11:51 am
mavrilimumab
sifalimumab
AstraZeneca
MedImmune
lupus
autoimmune disease
rheumatoid arthritis